- Home
- SLGB vs CALC Comparison
SLGB vs CALC Comparison
Compare SLGB & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | CALC |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 88.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLGB | CALC |
|---|---|---|
| Price | $1.20 | $5.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 297.4K | 96.2K |
| Earning Date | 02-16-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $99,438,843.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.69 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $0.92 | $1.42 |
| 52 Week High | $6.08 | $7.20 |
Technical Indicators
Market Signals| Indicator | SLGB | CALC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.90 |
| Support Level | N/A | $5.05 |
| Resistance Level | N/A | $5.71 |
| Average True Range (ATR) | 0.00 | 0.72 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 30.55 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.